Ratio Therapeutics announced today that it closed a $70 million Series C financing to support its radiopharmaceutical development and manufacturing. Existing investors Duquesne Family Office and Bristol Myers Squibb participated. New investors Catalio Capital Management, Eli Lilly and Wasatch Group joined as well. Boston-based Ratio plans to use the proceeds to fund its next phase…